The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.

摘要: Gliomas are the most frequently occurring primary brain tumor in central nervous system of adults. Glioblastoma multiformes (GBMs, WHO grade 4) have a dismal prognosis despite use alkylating agent, temozolomide (TMZ), and even low gliomas (LGGs, 2) eventually transform to malignant secondary GBMs. Although GBM patients benefit from promoter hypermethylation O(6)-methylguanine-DNA methyltransferase (MGMT) that is main determinant resistance TMZ, recent studies suggested MGMT methylation prognostic as well predictive significance for efficacy TMZ. Glioma-CpG island methylator phenotype (G-CIMP) global genome was shown be significant predictor improved survival with GBM. Collectively, we hypothesized might reflect DNA methylation. Additionally LGGs, still undetermined. In current study, aimed determine correlation between clinical, genetic, epigenetic profiles including LINE-1 different cancer-related genes clinical outcome newly diagnosed 57 LGG 54 patients. Here, demonstrated (1) IDH1/2 mutation closely correlated 1p/19q codeletion (2) levels GBMs lower than those LGGs normal tissues, (3) proportional gliomas, (4) higher favorable factor GBMs, compared As marker, may promising marker gliomas.